Physician profile
Deepika Misra
NPI 1538253711
$736.10
in general payments reported to CMS, 2019-2025
10 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.37 · 2020: $54.13 · 2021: $49.52 · 2022: $24.98 · 2023: $44.09 · 2024: $120 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $330.70 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $117.48 | 2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $63.49 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $52.30 | 2020-2021 | |
| Abbott Laboratories | $51.53 | 2022-2025 | Amplatzer |
| Edwards Lifesciences Corporation | $29.28 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.15 | 2020 | |
| Amgen INC. | $24.21 | 2023 | Repatha |
| Lantheus Medical Imaging, INC. | $19.88 | 2023 | Definity |
| Janssen Pharmaceuticals, INC | $18.08 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.